LPWM
NBIX icon

Lake Point Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Lake Point Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Hold
11
– – ﹤0.01% 394
2022
Q1 		$1K Hold
11
– – ﹤0.01% 392
2021
Q4 		$1K Hold
11
– – ﹤0.01% 401
2021
Q3 		$1K Hold
11
– – ﹤0.01% 372
2021
Q2 		$1K Buy
+11
New +$1.05K ﹤0.01% 383
2020
Q1 		$1K Hold
11
– – ﹤0.01% 341
2019
Q4 		$1K Buy
+11
New +$1.15K ﹤0.01% 573

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Lake Point Wealth Management's NBIX Position: Q2 2022 in Review

Lake Point Wealth Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2022 at 11 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #394.

Lake Point Wealth Management first reported a position in NBIX in Q4 2019 and has held it in 7 quarters since. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Lake Point Wealth Management held 11 shares of Neurocrine Biosciences worth $1K as of Q2 2022.
  • Lake Point Wealth Management left its Neurocrine Biosciences share count unchanged in Q2 2022.
  • Neurocrine Biosciences made up ﹤0.01% of Lake Point Wealth Management's portfolio in Q2 2022, its #394 holding.
  • Lake Point Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 7 quarters since.
  • 437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Lake Point Wealth Management's 13F filing for Q2 2022, filed 19 Jul 2022.